share_log

联康生物科技集团(00690.HK)：博固泰上市申请已正式获国家药监局批准为国产首款一次性预充笔式特立帕肽注射液

Liankang Biotechnology Group (00690.HK): Bogutai's marketing application has been officially approved by the State Drug Administration as the first disposable pre-filled teriparatide injection made in China

Gelonghui Finance ·  Jan 21 19:07

Gelonghui, January 22丨Liankang Biotechnology Group (00690.HK) announced that China's National Drug Administration (“NMPA”) approved the marketing application for Bogutai (teriparatide injection) independently developed by the Group on January 16, 2024. The application was accepted on June 28, 2022, and the approval number is “Sinopharm Standard S20240004”. Bogutai's approval for listing is a major milestone for the company in the field of orthopedic diseases, expanding the range of drug choices for patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment